Erasca, Inc.
ERAS
Rank in Stocks
#3619
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Share Price
$13.45
Last synced: 2026-10-16
Market Cap
$4.70B
Change (1 day)
-9.58%
Change (1 year)
455.58%
Country
US
Trade Erasca, Inc. (ERAS)
Category
Healthcare
Dividend history for Erasca, Inc. (ERAS)
Erasca, Inc. (stock symbol: ERAS) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Erasca, Inc. (ERAS) from 2026 to 2026
Annual dividend payments
| Year | Dividend (stock split adjusted) | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
List of all dividend payments
| Year | Dividend | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Dividend payments for similar companies or competitors
| Company | Number of dividend payments | Country |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
